References

bloodjour

Гематология и трансфузиология

Russian journal of hematology and transfusiology

0234-57302411-3042

ООО Издательский дом «Практика»

10.25837/HAT.2018.30..1..008

bloodjour-89

Research Article

ОБЗОР ЛИТЕРАТУРЫ

REVIEW ARTICLE

ПРИМЕНЕНИЕ КОНЦЕНТРАТОВ ПРОТРОМБИНОВОГО КОМПЛЕКСА ПО УТВЕРЖДЕННЫМ И НЕУТВЕРЖДЕННЫМ ПОКАЗАНИЯМ: НОВЫЕ ПЕРСПЕКТИВЫ СТАРЫХ ПРЕПАРАТОВ

LABEL AND OFF-LABEL APPLICATIONS OF PROTHROMBIN COMPLEX CONCENTRATES. NEW PERSPECTIVES OF OLD DRUGS

https://orcid.org/0000-0001-8818-8949

Галстян

Г. М.

Galstyan

G. M.

gengalst@gmail.com

ФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения России, МоскваРоссияNational Research Center for HematologyRussian Federation

2018

18042019

6317891

2019

Галстян Г.М.

Galstyan G.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.htjournal.ru/jour/article/view/89

Концентраты протромбинового комплекса (КПК), содержащие витамин K-зависимые факторы, были разработаны для реверсии действия антагонистов витаминов. Однако в последние годы КПК все чаще применяются по другим показаниям. Роль настоящего обзора — осветить применение КПК для лечения кровотечений при реверсии действия прямых оральных антикоагулянтов, при оперативных вмешательствах, травме, заболеваниях печени. Обсуждается также безопасность КПК.

The prothrombin complex concentrates (PCCs), containing therapeutic doses of vitamin K-dependent coagulation factors, were licensed for reversal of vitamin K antagonist therapy. However, recently clinicians sought to use PCCs for any number of off-label indications. The goal of this review is to explore practical issues regarding PCCs. Specifically, aims are to examine the role of PCCs in vitamin K antagonist reversal, review its potential use in the treatment of hemorrhage due to direct oral anticoagulants, and explore potential uses in liver disease, trauma-associated bleeding, etc. Safety and other practical considerations of PCCs will also be discussed.

концентраты протромбинового комплексафакторы свертывания кровиантикоагулянтыреверсия действия антикоагулянтовострое кровотечение

prothrombin complex concentratesblood coagulation factorsanticoagulantsanticoagulant reversalemergency bleeding

References1

Андреев Ю. Н. Многоликая гемофилия. — М.: НьюДиамед, 2006.

Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res 1999; 95:S7—12.

Seitz R, Dodt J. Virus safety of prothrombin complex concentrates and FIX concentrates. Thromb Res 1999; 95:S19—23.

Sorensen B, Spahn DR, Innerhofer P et al. Clinical review: Prothrombin complex concentrates — evaluation of safety and thrombogenicity. Crit Care 2011; 15:201. doi: 10.1186/cc9311.

Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95:S13—17.

Negrier C, Gomperts E, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia 2006; 12:4—13.

Giles AR, Nesheim ME, Hoogendoorn H et al. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59:401—407.

Pabinger I, Brenner B, Kalina U et al. Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6:622—631. doi:10.1111/j.1538-7836.2008.02904.x.

White GC, Roberts HR, Kingdon HS et al. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49:159—170.

Колосова И. В., Галстян Г. М., Орел Е. Б. и др. Терапия геморрагического синдрома, вызванного дефицитом витамин К-зависимых факторов свертывания крови. Гематология и трансфузиология 2012; 57:22—30.

Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008; 62:1614—1622.

Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care 2008, 12(4): R105. doi:10.1186/cc6987.

Van Aart L, Eijkhout HW, Kamphuis JS et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006; 118:313—320. doi:10.1016/j.thromres.2005.08.005.

Riess HB, Meier-Hellmann A, Motsch J et al. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121:9—16. doi:10.1016/j. thromres.2007.02.009.

Ostermann H, Haertel S, Knaub S et al. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007; 98:790—797.

Dargaud Y, Desmurs-Clavel H, Marin S et al. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study. J Thromb Haemost 2008; 6:962—968. doi:10.1111/j.1538- 7836.2008.02964.x.

Holt T, Taylor S, Abraham P et al. Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding. Int J Crit Illn Inj Sci 2018; 8:36—40. doi:10.4103/IJCIIS.IJCIIS.

Imberti D, Barillari G, Biasioli C et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus 2011; 9:148—155. doi:10.2450/2011.0065-10.

Herzog E, Kaspereit F, Krege W et al. Four-factor prothrombin complex concentrate (4F-PCC) is superior to three-factor prothombin comlex concentrates (3F-PCC) for reversal of coumarin anticoagulation. Blood 2014; 124:1472.

Mohan S, Howland MA, Lugassy D et al. The use of 3- and 4-factor prothrombin complex concentrate in patients with elevated INR. J Pharm Pract 2017; 31:262—267. doi:10.1177/0897190017707119.

Holland L, Warkentin TE, Refaai M et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49:1171—1177. doi:10.1111/j.1537- 2995.2008.02080.x.

Yuan S, Ferrell C, Chandler WL. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma. Thromb Res 2007; 120:29—37. doi:10.1016/j.thromres.2006.07.002.

Makris M, Van Veen JJ. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? Blood Transfus 2011; 9:117—119. doi:10.2450/2011.0111-10.

Blacker DJ. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2005; 182:365.

Horton JD, Bushwick BM. Warfarin therapy: Evolving strategies in anticoagulation. Am Fam Physician 1999; 59:634–646.

Tanaka KA, Bolliger D, Vadlamudi R et al. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth 2012; 26:1083—1093. doi: 10.1053/j. jvca.2012.06.015.

Schick KS, Fertmann JM, Jauch KW et al. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care 2009; 13:R191.

Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349:675—683.

Hanley JP. Warfarin reversal. J Clin Pathol 2004; 57:1132—1139.

Ghadimi K, Levy JH, Welsby IJ. Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 2016; 122:1287—1300. doi:10.1213/ANE.0000000000001188.

Tanaka KA, Mazzeffi M, Durila M. Role of prothrombin complex concentrate in perioperative coagulation therapy. J Intensive Care 2014; 2:60. doi: 10.1186/s40560-014-0060-5.

Ponschab M, Voelckel W, Pavelka M et al. Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma. Scand J Trauma Resusc Emerg Med 2015; 23:84. doi: 10.1186/s13049-015- 0165-4.

Gorlinger K, Dirkmann D, Hanke AA et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115:1179—1191. doi: 10.1097/ ALN.0b013e31823497dd.

Schochl H, Nienaber U, Maegele M et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15:R83. doi: 10.1186/cc10078.

Preston FE, Laidlaw ST, Sampson B et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116:619—624.

Boulis NM, Bobek MP, Schmaier A et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45:1113—1118.

Makris M, Greaves M, Phillips WS et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77:477—480.

Bohrer H. Prothrombin complex concentrate substitution during liver transplantation. Thromb Res 1999; 95:S71—74.

Chowdary P, Tang A, Watson D et al. Retrospective review of a prothrombin complex concentrate (Beriplex P/N) for the management of perioperative bleeding unrelated to oral anticoagulation. Clin Appl Thromb Hemost 2018:1076029617753537. doi: 10.1177/1076029617753537.

Hellstern P, Halbmayer WM, Kohler M et al. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res 1999; 95:S3—6.

Lorenz R, Kienast J, Otto U et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003; 15:15—20.

Carvalho MC, Rodrigues AG, Conceicao LM et al. Prothrombin complex concentrate (Octaplex): A portuguese experience in 1152 patients. Blood Coagul Fibrinolysis 2012; 23:222—228.

Unold D, Tormey CA. Clinical applications of 4-factor prothrombin complex concentrate: A practical pathologist’s perspective. Arch Pathol Lab Med 2015; 139:1568—1575.

Kaspereit F, Hoffmann S, Pragst I et al. Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model. Br J Anaesth 2010; 105:576—582.

Solomon C, Hagl C, Rahe-Meyer N. Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth 2013; 110:947—956.

Ortmann E, Besser MW, Sharples LD et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015; 121:26—33.

Demeyere R, Gillardin S, Arnout J et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 99:251—260.

Fraser TA, Corke CF, Mohajeri M et al. A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Crit Care Resusc 2006; 8:141—145.

Fitzgerald J, Lenihan M, Callum J et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: A propensity score matched comparison to plasma. Br J Anaesth 2018; 120:928—934. doi: 10.1016/j.bja.2018.02.017.

Sun GH, Patel V, Moreno-Duarte I et al. Intraoperative administration of 4-factor prothrombin complex concentrate reduces blood requirements in cardiac transplantation. J Cardiothorac Vasc Anesth 2018; 32:161—167.

Kozek-Langenecker SA, Ahmed AB, Afshari A et al. Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology. First update 2016. Eur J Anaesthesiol 2017; 34:332—395. doi: 10.1097/EJA.0000000000000630.

American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology 2015; 122:241—275. doi:10.1097/ALN.0000000000000463.

Rossaint R, Bouillon B, Cerny V et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016; 20:100. doi: 10.1186/s13054-016-1265-x.

Dickneite G, Doerr B, Kaspereit F. Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. Anesth Analg 2008; 106:1070—1077.

Fries D, Haas T, Klingler A et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy — a porcine model. Br J Anaesth 2006; 97:460—467.

Pragst I, Kaspereit F, Dorr B et al. Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model. Thromb Res 2010; 125:272—277.

Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth 2009; 102:345—354.

Fenger-Eriksen C, Tonnesen E, Ingerslev J et al. Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. J Thromb Haemost 2009; 7:1099—1105.

Mendarte L, Munne M, Rodriguez S et al. Use of human prothrombin complex concentrate in patients with acquired deficiency and active or in high-risk severe bleeding. J Coagul Disord 2010; 2:1—7.

Jehan F, Aziz H, O’Keeffe T et al. The role of 4-factor prothrombin complex concentrate (4-PCC) in coagulopathy of trauma: A propensity matched analysis. J Trauma Acute Care Surg 2018; doi: 10.1097/TA.0000000000001938. [Epub ahead of print]

Younis M, Ray-Zack M, Haddad NN et al. Prothrombin complex concentrate reversal of coagulopathy in emergency general surgery patients. World J Surg 2018; doi: 10.1007/s00268-018-4520-2. [Epub ahead of print]

Halvorsen S, Ghanima W, Fride Tvete I et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Hear J Cardiovasc Pharmacother 2017; 3:28—36. doi: 10.1093/ehjcvp/pvw031.

Adeboyeje G., Sylwestrzak G, Barron JJ et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2017; 23:968—978. doi: 10.18553/jmcp.2017.23.9.968.

Levi M, Moore KT, Castillejos CF et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12:1428—1436.

Yoshimura S, Sato S, Todo K et al. Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants: The SAMURAI-NVAF study. J Neurol Sci 2017; 375:1507. doi: 10.1016/j.jns.2017.01.041.

EerenbergES, KamphuisenPW, SijpkensMK etal. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573—1579. doi: 10.1161/CIRCULATIONAHA.111.029017.

Solbeck S, Meyer MA, Johansson PI et al. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int J Cardiol 2014; 176:794—799. doi: 10.1016/j.ijcard.2014.07.084.

Schenk B, Goerke S, Beer R et al. Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: A single-center pilot trial. Thromb J 2018; 16:1. doi: 10.1186/s12959-017-0158-9.

Schulman S, Gross PL, Ritchie B et al. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: A prospective cohort study. Thromb Haemost 2018; doi: 10.1055/s-0038-1636541. [Epub ahead of print]

Majeed A, Agren A, Holmstrom M et al. Management of rivaroxabanor apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130:1706—1712.

Faust AC, Tran DM, Lo C et al. Managing nonoperable intracranial bleeding associated with apixaban: A series of 2 cases. J Pharm Pract 2018; 31:107—111.

Levy JH, Moore KT, Neal MD et al. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. J Thromb Haemost 2018; 16:54—64.

Majeed A, Eelde A, Agren A et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 2012; 129:146—151.

Sohraby R. Coagulation factors in controlling traumatic bleeds: FFP, PCC, or lucky sevens? CiteSeer 2012;1—19. Доступно в интернете по адресу: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.636.6823&rep=rep1&type=pdf (просматривалось 4 мая 2018 г.).

Bayram I, Erbey F, Erdem S et al. Recombinant factor VIIa and activated prothrombin-complex concentrate administration in the management of bleeding, coagulopathy and intractable coagulopathy in pediatric patients undergoing invasive medical procedures or surgery. Int J Hematol Oncol 2009; 19:205—212.

Chapman SA, Irwin ED, Abou-Karam NM et al. Comparison of 3-factor prothrombin complex concentrate and low-dose recombinant factor VIIa for warfarin reversal. World J Emerg Surg 2014; 9:27. doi: 10.1186/1749-7922-9-27.

Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119:643—651.

Tanaka KA, Mazzeffi MA, Grube M et al. Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery prothrombin. Transfusion 2013; 53:920—921.

Mehringer SL, Klick Z, Bain J et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Ann Pharmacother 2018; 52:533—537.

Joseph B, Hadjizacharia P, Aziz H et al. Prothrombin complex concentrate: An effective therapy in reversing the coagulopathy of traumatic brain injury. J Trauma Acute Care Surg 2013; 74:248—253.

The authors declare that there are no conflicts of interest present.